Efficacy of Vunakizumab in Erosive haNd osteoarthritiS (VENuS): protocol for a multicentre, randomised controlled trial - PubMed
12 hours ago
- #Clinical Trial
- #Osteoarthritis
- #IL-17 Inhibitor
- Study evaluates vunakizumab, an IL-17A inhibitor, for erosive hand osteoarthritis (OA).
- Multicentre, randomised, placebo-controlled trial with 150 participants aged 30-80.
- Primary outcome: change in hand pain (Visual Analogue Scale) at 28 weeks.
- Secondary outcomes include functional improvements and radiographic/MRI evaluations.
- Ethics approval obtained; results to be published in peer-reviewed journals.